Role of Vitamin D in the Onset,Progression, and Severity of Multiple Sclerosis |
| |
| Institution: | 1. Division of Endocrinology; and University of Florida College of Medicine-Jacksonville, Jacksonville, Florida;2. Division of Endocrinology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida;1. Medical Director, Metabolic Institute of America, Tarzana, California;2. Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan;3. Clinical Professor, Department of Medicine, The Mount Sinai School of Medicine, New York, New York;4. Pediatric Endocrinology, National Institutes of Health, Bethesda, Maryland;5. Director, Medical Development, and Senior Vice President, Research & Development, Amylin Pharmaceuticals, Inc., San Diego, California;6. Medical Director, Scripps Whittier Diabetes Institute, La Jolla, California;7. Professor of Medicine, Biochemistry & Molecular Biology and Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas;8. Professor of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas;9. UAB Diabetes Research and Training Center, University of Alabama at Birmingham, Birmingham, Alabama;10. Chairman, Grunberger Diabetes Institute, Bloomfield Hills, Michigan;11. Professor of Medicine, University of California, San Diego, California;12. The Endocrinology, Weight Control and Metabolic Center, Tarzana, California;13. Pediatric Endocrinology Clinic, East Tennessee Children’s Hospital, Knoxville, Tennessee.;1. Division of Endocrinology, Department of Medicine, Washington Hospital Center, Washington, DC;2. Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland;3. Division of Nuclear Medicine, Department of Medicine, Washington Hospital Center, Washington, DC;4. Department of Biostatistics and Bioinformatics, Medstar Health Research Institute, Hyattsville, MD;5. Georgetown-Howard Universities Center for Clinical and Translational Sciences, Washington, DC (GHUCCTS-CTSA);6. Division of Endocrinology and Medicine, Department of Medicine, Georgetown''s University Hospital, Washington, DC |
| |
| Abstract: | ObjectiveTo review and assess the role of vitamin D in the onset, progression, and relapse of multiple sclerosis (MS), based on evidence acquired from the analysis of preclinical, observational, and interventional studies.MethodsAll English language literature in MEDLINE (January 1969 through April 2012) was searched for observational and interventional studies on the dosage effect of vitamin D on the onset, progression, and relapse rate of MS. The medical subject heading (MeSH) terms used in the search included Vitamin D and Multiple Sclerosis. Additional publications and abstracts were identified from review articles and from the references cited in the previously found articles. In addition to the experimental studies, only those human studies that specified the population size, doses of vitamin D used, and the resulting effect on MS were considered.ResultsVitamin D deficiency is very common among MS patients. Multiple preclinical studies have shown that vitamin D is a potent regulator of inflammation in MS. Most observational studies support an association between high vitamin D levels and a reduced risk of developing MS. However, conflicting results have been reported by observational studies on the correlation between vitamin D and MS severity and by interventional studies using vitamin D as a therapeutic agent for MS.ConclusionVitamin D deficiency in MS patients should be avoided. In addition, the risk of developing MS might be reduced by maintaining optimal vitamin D levels in the healthy population. Larger randomized interventional trials are needed to clarify the therapeutic effect of vitamin D in MS. (Endocr Pract. 2013;19:129-136) |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
